Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (173)	12/17/2003 1:46:20 AM
From: tuck	Read Replies (1) \| Respond to of 510

To my knowledge, this is this first attempt to use SELDI to find multiple biomarkers for RCC. OTOH, the abstract says nothing of sensitivity and specificity. Wonder if they've already filed the patent app on those molecular weights for this application. These are pretty low mass proteins, BTW . . . >>Proteomics. 2003 Dec;3(12):2310-6. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Department of Computer Engineering, Chonnam National University, Gwangju, Korea. Despite having a relatively low incidence, renal cell carcinoma (RCC) is one of the most lethal urologic cancers. For successful treatment including surgery, early detection is essential. Currently there is no screening method such as biomarker assays for early diagnosis of RCC. Surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF) is a recent technical advance that can be used to identify biomarkers for cancers. In this study, we investigated whether SELDI protein profiling and artificial intelligence analysis of serum could distinguish RCC from healthy persons and other urologic diseases (nonRCC). The SELDI-TOF data was acquired from a total of 36 serum samples with weak cation exchange-2 protein chip arrays and filtered using ProteinChip software. We used a decision tree algorithm c4.5 to classify the three groups of sera. Five proteins were identified with masses of 3900, 4107, 4153, 5352, and 5987 Da. These biomarkers can correctly separate RCC from healthy and nonRCC samples.<< Cheers, Tuck